ABCIXIMAB

Course overview

ABCIXIMAB IS WIDELY USED IN INTERVENTIONAL CARDIOLOGY FOR THE TREATMENT OF UNSTABLE ANGINA AND AS AN ADJUNCT THERAPY FOLLOWING PERCUTANEOUS CORONARY INTERVENTION. ABCIXIMAB IS A GLYCOPROTEIN IIB/IIIA INHIBITOR THAT INHIBITS PLATELET AGGREGATION BY REVERSIBLY BINDING TO PLATELET IIB/IIIA RECEPTORS, RESULTING IN STERIC HINDRANCE. ITS RELATIVELY SHORT HALF-LIFE OF ABOUT THIRTY MINUTES CAN BE BENEFICIAL IF USED AS A SHORT-TERM PLATELET AGGREGATION INHIBITOR FOR PATIENTS THAT ARE ON THEIR WAY TO THE CATHETERIZATION LAB FOR PERCUTANEOUS CORONARY INTERVENTION. THIS ACTIVITY REVIEWS THE INDICATIONS, ADMINISTRATION, AND POTENTIAL ADVERSE EFFECTS OF THIS MEDICATION, AND HIGHLIGHTS THE ROLE OF THE INTERPROFESSIONAL TEAM IN CARING FOR PATIENTS TREATED WITH THIS MEDICATION.